Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials

Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials

Abstract Heart failure (HF) treatment has changed substantially over the last 30 years, leading to significant reductions in mortality and hospital admissions in patients with HF with reduced ejection fraction (HFrEF). Currently, the optimization of guideline‐directed chronic HF therapy remains the...

Full description

Bibliographic Details
Main Authors: Amr Abdin, Martin Schulz, Uwe Riemer, Bledar Hadëri, Rolf Wachter, Ulrich Laufs, Johann Bauersachs, Ingrid Kindermann, Davor Vukadinović, Michael Böhm
Format: Article
Language:English
Published: Wiley 2022-12-01
Series:ESC Heart Failure
Subjects:
Heart failure
Sacubitril/valsartan
Efficacy
Effectiveness
Safety
Implementation
Online Access:https://doi.org/10.1002/ehf2.14097

Internet

https://doi.org/10.1002/ehf2.14097

Similar Items